New drug interaction study for myelofibrosis treatment begins

NCT ID NCT06024915

Completed Knowledge-focused Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1 trial in 40 healthy adults tests how TQ05105, a drug for myelofibrosis, interacts with other medications that affect liver enzymes. Participants take TQ05105 alone and then with either itraconazole or rifampicin to see how these drugs change TQ05105 levels in the body. The goal is to understand safety and dosing for future use in patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQ05105 tablets (a JAK2 inhibitor)
What this could lead to: If successful, this study could help doctors understand how to safely combine TQ05105 with other medications for myelofibrosis patients.
What could go wrong: This is a very early phase 1 study in healthy volunteers, not patients. It only tests drug interactions, not whether TQ05105 works for myelofibrosis. Results may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Locations

Shandong Provincial Hospital

Jinan, Shandong, 250021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.